Objective To explore the levels of serum chemokine in the patients with gastric cancer using cytometric beads array (CBA) and to find out the laboratory evidence for gastric cancer immunotberapy.Methods Forty-five patients with gastric cancer,thirty patients with benign gastric diseases and forty healthy controls were included.The chemokine levels of interleukin-8 (IL-8),regulated upon activation normal T-cell expressed and secreted (RANTES),monokine induced by IFN-γ (MIG),monocyte ehemoattractant protein-1(MCP-1) and interferon-γ induced protein-10 (IP-10) in serum of these three groups were measured using CBA ,then these data were analyzed using BD CBA analysis software.Results The levels of serum chemokines in healthy controls were (176.4±20.7) μg/L for IP-10,(111.3±17.2) μg/L for MCP-1,(503.9±47.2) μg/L for MIG,(472.4±116.7) μg/L for IL-8,respectively.In gastric cancer patients,the levels were (266.6±24.7) μg/L for IP-10,(100.4,70.8-193.5) μg/L for MCP-1,(1614±275.4) μg/L for MIG,(500.0±164.8) μg/L for IL-8.The levels of serum chemokines in patients with benign gastric disease were (207.9±31.7) μg/L for IP-10,(121.2±23.6) μg/L for MCP-1,(514.5±63.0) μg/L for MIG,(480.2±134.8) μg/L for IL-8,respectively.The levels of IP-10 and MIG among these three groups were significantly different (IP-10:F = 3.52,P < 0.05,MIG:F = 9.27,P < 0.01).The levels of IP-10 were elevated in the cancer patients compared with healthy controls (P < 0.05),while the levels of MIG were elevated significantly in the cancer patients compared with healthy controls and benign disease controls(t=3.29,P < 0.01,t=2.84,P<0.01).Conclusions CBA is a novel method with convenience,sensitivity and accuracy for the detection of serum ehemokines.The concentration of IP-10 and MIG in gastric cancer patients are elevated,indicating its implication in cancer pathogenesis and metastasis.Measurement of serum chemokines will lay the groundwork for therapeutic strategy in gastric cancer by inhibiting and anti-chemokine.%目的 探讨流式微球阵列分析术(cytometric bead array,CBA)检测胃癌患者血清中趋化因子含量及其临床意义,为胃癌免疫治疗提供依据.方法 收集45例胃癌患者、30例良性胃病患者和40名健康对照者血清,采用CBA测定3组血清中趋化因子[白细胞介素8(IL-8)、调节活化蛋白(RANTES)、γ干扰素诱导的单核因子(MIG)、巨噬细胞趋化蛋白-1(MCP-1)、干扰素-γ诱生蛋白(IP-10)]含量,并用BD公司CBA分析软件进行数据分析.结果 健康对照组血清趋化因子水平分别为IP-10(176.4±20.7)μg/L,MCP-1(111.3±17.2)μg/L,MIG(503.9±47.2)μg/L,IL-8(472.4±116.7)μg/L,良性胃病组为IP-10(207.9±31.7)μg/L,MCP-1(121.2±23.6)μg/L,MIG(514.5±63.0)μg/L,IL-8(480.2±134.8)μg/L,胃癌组为IP-10(266.6±24.7)μg/L,MCP-1(100.4,70.8～193.5)μg/L,MIG(1614.0±275.4)μg/L,IL-8(500.0±164.8)μg/L.3组血清IP-10、MIG水平差异具有统计学意义(IP-10:F=3.52,P<0.05,MIG:F=9.27,P<0.01).其中,胃癌组与健康对照组比较,血清IP-10含量差异有统计学意义(t=2.58,P<0.05);胃癌组与健康对照及良性胃病组比较,血清MIG含量差异均有统计学意义(分别t=3.29,P<0.01,t=2.84,P<0.01).结论 CBA检测血清趋化因子是一种简便、精确的新方法.胃癌患者血清趋化因子IP-10、MIG水平升高,可能与其发病、转移等过程有关,这些指标的检测将为采用趋化因子的抑制或拮抗作用治疗胃癌提供重要手段.
展开▼
